UPDATE 1-Bolivia signs J&J vaccine deal with a twist - it needs WTO patent waiver [Reuters]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Reuters
Americas Bolivia signs J&J vaccine deal with a twist - it needs WTO patent waiver Bolivia's government said on Tuesday it had signed a deal for a potential 15 million Johnson & Johnson (JNJ.N) COVID-19 vaccines but with a twist: another manufacture would make the shots and Bolivia would need the World Trade Organization to waive the drug's patent. The South American country, scrabbling for vaccines like many in the region, said it had applied to the WTO to green-light a vaccine waiver so Canadian company Biolyse Pharma Corp could make the doses. Bolivian trade official Benjamin Blanco told a news conference the move could help the impoverished Andean nation speed up a slow vaccination process. So far, Bolivia has reached just 10% of its population with a single dose. A deal has been signed for Biolyse Pharma - known for making court challenges to Big Pharma patents - to make the single-dose drug, which would be priced at between $3 and $4 a dose, Blanco said. "Getting someone who can
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson receives positive CHMP opinion for RYBREVANT®? (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations [Yahoo! FinaYahoo! Fina
- Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data [Seeking Alpha]Seeking Alpha
- AACN's New Web Resource Focuses on Preparing Nurses with Essential Well-Being and Leadership Competencies [Yahoo! Finance]Yahoo! Finance
- Justice Department is investigating McKinsey consulting firm's role in opioid epidemic [CNN]CNN
- BioNJ Announces Lineup for BioPartnering Conference [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 4/16/24 - Form 8-K/A
- 4/16/24 - Form 8-K
- 3/27/24 - Form PX14A6G
- JNJ's page on the SEC website